TYK MEDICINES-B (02410): Chairman, Executive Director and President intends to further increase shareholding in the Company
TYK MEDICINES-B (02410) announced that Dr. Wu Yusheng (Dr. Wu), Chairman, Executive Director and President of the Company, has informed the Company that Dr. Wu expects to further purchase shares of the Company in the open market, with the total amount of this increase currently expected not to exceed HK$2 million. Dr. Wu has undertaken to the Company that the shares of the Company acquired through the increase will be voluntarily locked up for six months from the date of purchase respectively, and that he will not sell or otherwise transfer the relevant shares during the lock-up period. Dr. Wu stated that the funds for this share increase come from his own funds. This share increase demonstrates his firm belief and full confidence in the future development prospects of the Group.
TYK MEDICINES-B (02410) announced that Dr. Wu Yusheng (Dr. Wu), Chairman, Executive Director and President of the Company, has informed the Company that Dr. Wu expects to further purchase shares of the Company in the open market, with the total amount of this increase currently expected not to exceed HK$2 million. Dr. Wu has undertaken to the Company that the shares of the Company acquired through this increase within the next month will be voluntarily locked up for six months from the date of purchase respectively, and that he will not sell or otherwise transfer the relevant shares during the lock-up period. Dr. Wu stated that the funds for this share increase come from his own funds. This share increase demonstrates his firm belief in and full confidence in the future development prospects of the Group.
Related Articles

New stock news | Hearing passed! Kunlun New Materials' half-year results exceed the whole of last year, and the world's third-largest independent electrolyte manufacturer is about to list on the Hong Kong stock market.

BAMA TEA (06980) responds to suspension of military procurement qualification: it is a qualification adjustment in a specific field and has no impact on the group's public-facing sales, operations, and core business.

YUM CHINA (09987) repurchased approximately 111,500 shares for approximately US$5.5999 million on November 20.
New stock news | Hearing passed! Kunlun New Materials' half-year results exceed the whole of last year, and the world's third-largest independent electrolyte manufacturer is about to list on the Hong Kong stock market.

BAMA TEA (06980) responds to suspension of military procurement qualification: it is a qualification adjustment in a specific field and has no impact on the group's public-facing sales, operations, and core business.

YUM CHINA (09987) repurchased approximately 111,500 shares for approximately US$5.5999 million on November 20.






